Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

By N. Casadevall, J. Nataf, B. Virón, A. Kolta, J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier and 2 more. New England Journal of Medicine, 2002

1,183 citations recorded by the source corpus.

Subfields: Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/b428f6b9c81b5dfa00ceceecbff9ec170c7bbd3f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. J. Drucker
2. M. Nauck
3. Ralph DeFronzo

Citations in the corpus

• mRNA-based therapeutics — developing a new class of drugs (2014, neutral): “A prominent example is the induction of neutralizing antibodies to therapeutic erythropoietin that caused red cell aplasia in monkeys and humans by crossreacting with endogenous erythropoietin 192–194 .”
• Enhancing incretin action for the treatment of type 2 diabetes. (2003, background): “The known immunogenic potential of even identical recombinant human therapeutic proteins (172) raises the specter of immunoneutralizing antibodies in some patients, which may lead to reduction in therapeutic efficacy or potential exacerbation of diabetes if the antibodies cross-react with endogenous”